ClinicalTrials.gg
RecruitingNCT06772220Updated Jan 13, 2025

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

An interventional study of Folic Acid 1 MG and Vitamin B6 25 MG in Parkinson&Amp;#39;s Disease, sponsored by Oregon Health and Science University. Recruiting at 1 site in United States. Open to participants aged 40 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-01-13.

Sponsored by Oregon Health and Science University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Mar 2024, registered Jan 2025).
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
40 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Parkinson Disease by Oregon Health and Science University — 4 open to participants now, 4 under way, none of them phase 3. Parkinson Disease · Oregon Health and Science University.

Planned enrollment
2nd of 28
150 · median 22
Started
2024
the only one that year
No phase
17 of 36
4 open now
Registered
35th of 36
by date

Among the 36 studies in Parkinson Disease by Oregon Health and Science University, this one is the 2nd largest by planned enrollment of the 28 interventional ones that give a count, is the only one that started in 2024, is one of 17 with no phase, and was the 35th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

4 of the 36 studies in Parkinson Disease by Oregon Health and Science University are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Parkinson Disease by Oregon Health and Science University, or all of them as a file.
02

Study summary

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

03

Conditions studied

  • Parkinson&Amp;#39;s Disease

Browse trials for

Keywords

  • Parkinson's disease
  • Parkinson disease
  • homocysteine
04

Who can participate

Ages eligible
40 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria.
  2. Currently treated with levodopa at a minimum dose of 300 mg/day
  3. (MOCA) ≥15
  4. Demonstrated capacity to provide .
  5. 40-90 years of age
  6. Estimated ≥60
  7. Absence of uncontrolled hypertension in medical history
  8. Absence of insulin use

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    B vitamin regimen

    Daily doses of 1mg folic acid, 25mg vitamin B6, and 1,000 ug vitamin B12.

    Dietary Supplement: Folic Acid 1 MG · Dietary Supplement: Vitamin B6 25 MG · Dietary Supplement: Vitamin B12

  • No intervention
    No vitamins

    No vitamin intervention.

Interventions

06

What researchers measure

Primary outcomes

  1. Hyperhomocysteinemia and B vitamin deficiency

    Plasma vitamin B12 in subjects with vs without hyperhomocysteinemia

    Time frame: baseline measurement

  2. Hyperhomocysteinemia and B vitamin deficiency

    Plasma folic acid in subjects with vs without hyperhomocysteinemia

    Time frame: baseline measurement

  3. Hyperhomocysteinemia and B vitamin deficiency

    Plasma pyridoxine in subjects with vs without hyperhomocysteinemia

    Time frame: baseline measurement

Secondary outcomes

  1. Hyperhomocysteinemia and cognitive assessments

    Change in total Braincheck score in subjects with vs without hyperhomocysteinemia

    Time frame: From enrollment to the end of treatment at 3 months

  2. Hyperhomocysteinemia and measurement of neurofilament light in plasma

    Change in plasma neurofilament level in subjects with vs without hyperhomocysteinemia

    Time frame: From enrollment to the end of treatment at 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2025, 21 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 21 months is below that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 13, 2025
StartActual
Mar 5, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2025
Last update
Jan 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06772220
Responsible party
Joseph Quinn (OHSU Parkinson Center Director, Oregon Health and Science University) — Principal investigator
First posted
Jan 13, 2025
Start date
Mar 5, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 13, 2025

Study contacts

Madeline Armendariz Sullivan
Contact
PDResearch@ohsu.edu
503-501-8478
Joseph Quinn, MD
principal investigator · Oregon Health & Science University (OHSU)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Folic Acid · Vitamin B 6 · Pyridoxine · Vitamin B 12

Start the discussion